AMLX
Amylyx Pharmaceuticals, Inc.
Price Chart
Latest Quote
$14.67
Current Price| Previous Close | $14.29 |
| Open | $14.29 |
| Day High | $15.00 |
| Day Low | $14.29 |
| Volume | 1,062,638 |
Stock Information
| Shares Outstanding | 109.82M |
| Total Debt | $5.93M |
| Cash Equivalents | $343.99M |
| Revenue | $-665K |
| Net Income | $-149.28M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.61B |
| EPS (TTM) | $-1.79 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 19/42| Debt to Equity | 0.01 |
| Debt to Earnings | -0.05 |
| Current Ratio | 6.67 |
| Quick Ratio | 6.23 |
| Profit Margin | -345.36% |
| Return on Equity | -183.14% |
| Avg FCF Growth | 30.82% |
| FCF Yield | -10.42% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $14.67 | 1,166,500 |
| 2026-01-30 | $14.29 | 2,262,100 |
| 2026-01-29 | $14.85 | 1,503,800 |
| 2026-01-28 | $14.51 | 972,400 |
| 2026-01-27 | $15.47 | 1,673,000 |
| 2026-01-26 | $15.01 | 1,541,500 |
| 2026-01-23 | $15.76 | 1,379,300 |
| 2026-01-22 | $16.23 | 2,153,000 |
| 2026-01-21 | $16.92 | 3,601,400 |
| 2026-01-20 | $16.55 | 4,419,500 |
| 2026-01-16 | $14.30 | 1,714,500 |
| 2026-01-15 | $13.52 | 2,364,900 |
| 2026-01-14 | $14.07 | 1,796,500 |
| 2026-01-13 | $12.60 | 1,227,200 |
| 2026-01-12 | $12.39 | 1,043,100 |
| 2026-01-09 | $12.21 | 1,209,500 |
| 2026-01-08 | $11.83 | 2,308,800 |
| 2026-01-07 | $11.99 | 1,457,500 |
| 2026-01-06 | $11.38 | 2,082,800 |
| 2026-01-05 | $11.39 | 2,101,000 |
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million
Motley Fool âĸ 2026-02-01T05:09:44Z
How Investors May Respond To Gubra (CPSE:GUBRA) Securing Amylyx GLP-1 Milestones And Royalty Upside
Simply Wall St. âĸ 2026-01-22T20:12:01Z
Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders
Insider Monkey âĸ 2026-01-19T13:01:59Z
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage
Simply Wall St. âĸ 2026-01-11T18:09:17Z
Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases
Insider Monkey âĸ 2026-01-10T19:57:04Z
Amylyx selects AMX0318 as development candidate for PBH
TipRanks âĸ 2026-01-09T12:16:47Z
Amylyx pins its next hopes on a niche drug in the obesity space
Pharma Voice âĸ 2025-12-12T09:35:51Z
Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)?
Simply Wall St. âĸ 2025-12-09T23:12:41Z
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million â Should Investors Follow?
Motley Fool âĸ 2025-12-09T12:20:01Z
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
Motley Fool âĸ 2025-12-03T15:05:02Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $124,633,000 | $25,441,000 | $2,993,000 | $0 |
| Cost Of Revenue | $124,633,000 | $25,441,000 | $2,993,000 | $0 |
| Total Revenue | $87,371,000 | $380,786,000 | $22,230,000 | $0 |
| Operating Revenue | $114,265,000 | $431,433,000 | $27,104,000 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $343,048,000 | $341,984,000 | $223,571,000 | $82,688,000 |
| Other Income Expense | $-60,268,000 | $-660,000 | $-551,000 | $-5,279,000 |
| Other Non Operating Income Expenses | $-1,214,000 | $-660,000 | $-551,000 | $-5,279,000 |
| Net Non Operating Interest Income Expense | $13,809,000 | $16,155,000 | $4,291,000 | $36,000 |
| Operating Expense | $218,415,000 | $316,543,000 | $220,578,000 | $82,688,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Other Operating Expenses | - | - | - | $-285,000 |
| General And Administrative Expense | - | - | - | $38,933,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-301,743,000 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Net Interest Income | $13,809,000 | $16,155,000 | $4,291,000 | $36,000 |
| Interest Income | $13,809,000 | $16,155,000 | $4,291,000 | $36,000 |
| Normalized Income | $-242,748,054 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Net Income From Continuing And Discontinued Operation | $-301,743,000 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Total Operating Income As Reported | $-314,731,000 | $38,802,000 | $-201,341,000 | $-82,688,000 |
| Net Income Common Stockholders | $-301,743,000 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Net Income | $-301,743,000 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Net Income Including Noncontrolling Interests | $-301,743,000 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Net Income Continuous Operations | $-301,743,000 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Pretax Income | $-302,136,000 | $54,297,000 | $-197,601,000 | $-87,931,000 |
| Special Income Charges | $-59,054,000 | $0 | - | - |
| Interest Income Non Operating | $13,809,000 | $16,155,000 | $4,291,000 | $36,000 |
| Operating Income | $-255,677,000 | $38,802,000 | $-201,341,000 | $-82,688,000 |
| Gross Profit | $-37,262,000 | $355,345,000 | $19,237,000 | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-4.43 | $0.70 | $-3.39 | $-1.59 |
| Basic EPS | $-4.43 | $0.73 | $-3.39 | $-1.59 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-59,054 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-195,719,000 | $39,890,000 | $-200,854,000 | $-82,636,000 |
| Total Unusual Items | $-59,054,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-59,054,000 | $0 | - | - |
| Reconciled Depreciation | $904,000 | $1,088,000 | $487,000 | $52,000 |
| EBITDA (Bullshit earnings) | $-254,773,000 | $39,890,000 | $-200,854,000 | $-82,636,000 |
| EBIT | $-255,677,000 | $38,802,000 | $-201,341,000 | $-82,688,000 |
| Diluted Average Shares | $68,142,158 | $69,991,340 | $58,495,587 | $55,216,013 |
| Basic Average Shares | $68,142,158 | $67,234,465 | $58,495,587 | $55,216,013 |
| Diluted NI Availto Com Stockholders | $-301,743,000 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Tax Provision | $-393,000 | $5,026,000 | $774,000 | $0 |
| Other Special Charges | $36,203,000 | - | - | - |
| Restructuring And Mergern Acquisition | $22,851,000 | $0 | - | - |
| Research And Development | $104,084,000 | $128,187,000 | $93,450,000 | $44,040,000 |
| Selling General And Administration | $114,331,000 | $188,356,000 | $127,128,000 | $38,933,000 |
| Other Gand A | - | - | - | $38,933,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $164,765,000 | $433,432,000 | $340,607,000 | $-151,168,000 |
| Total Assets | $193,634,000 | $517,454,000 | $391,453,000 | $105,614,000 |
| Total Non Current Assets | $4,202,000 | $52,788,000 | $9,320,000 | $663,000 |
| Other Non Current Assets | $1,470,000 | $46,377,000 | $1,185,000 | $189,000 |
| Current Assets | $189,432,000 | $464,666,000 | $382,133,000 | $104,951,000 |
| Other Current Assets | $12,484,000 | $14,931,000 | $10,113,000 | $5,392,000 |
| Inventory | $0 | $38,323,000 | $9,769,000 | $0 |
| Receivables | $447,000 | $40,050,000 | $15,306,000 | $0 |
| Accounts Receivable | $447,000 | $40,050,000 | $15,306,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $176,501,000 | $371,362,000 | $346,945,000 | $96,118,000 |
| Cash And Cash Equivalents | $77,391,000 | $170,201,000 | $62,526,000 | $50,191,000 |
| Current Deferred Assets | - | - | $0 | $3,441,000 |
| Prepaid Assets | - | - | - | $5,392,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $1,981,000 | $4,237,000 | $6,277,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $463,000 | $1,980,000 | $4,237,000 | $0 |
| Current Debt And Capital Lease Obligation | $1,518,000 | $2,257,000 | $2,040,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $28,869,000 | $84,022,000 | $50,846,000 | $256,782,000 |
| Total Non Current Liabilities Net Minority Interest | $463,000 | $1,980,000 | $4,237,000 | $239,386,000 |
| Current Liabilities | $28,406,000 | $82,042,000 | $46,609,000 | $17,396,000 |
| Payables And Accrued Expenses | $16,896,000 | $62,995,000 | $29,338,000 | $13,116,000 |
| Payables | $2,939,000 | $22,061,000 | $6,257,000 | $4,372,000 |
| Accounts Payable | $2,939,000 | $22,061,000 | $6,257,000 | $4,372,000 |
| Non Current Deferred Liabilities | - | - | $0 | $35,000 |
| Other Current Liabilities | - | - | $4,596,000 | - |
| Other Payable | - | - | $1,358,000 | - |
| Tradeand Other Payables Non Current | - | - | - | $0 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $164,765,000 | $433,432,000 | $340,607,000 | $-151,168,000 |
| Total Equity Gross Minority Interest | $164,765,000 | $433,432,000 | $340,607,000 | $-151,168,000 |
| Stockholders Equity | $164,765,000 | $433,432,000 | $340,607,000 | $-151,168,000 |
| Gains Losses Not Affecting Retained Earnings | $-92,000 | $197,000 | $-86,000 | $9,000 |
| Other Equity Adjustments | $-92,000 | $197,000 | $-86,000 | $9,000 |
| Retained Earnings | $-606,692,000 | $-304,949,000 | $-354,220,000 | $-155,845,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 | $239,351,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $68,629,738 | $67,707,432 | $66,512,011 | $55,216,013 |
| Share Issued | $68,629,738 | $67,707,432 | $66,512,011 | $55,216,013 |
| Tangible Book Value | $164,765,000 | $433,432,000 | $340,607,000 | $-151,168,000 |
| Invested Capital | $164,765,000 | $433,432,000 | $340,607,000 | $-151,168,000 |
| Working Capital | $161,026,000 | $382,624,000 | $335,524,000 | $87,555,000 |
| Capital Lease Obligations | $1,981,000 | $4,237,000 | $6,277,000 | $0 |
| Total Capitalization | $164,765,000 | $433,432,000 | $340,607,000 | $-151,168,000 |
| Additional Paid In Capital | $771,542,000 | $738,177,000 | $694,906,000 | $4,667,000 |
| Capital Stock | $7,000 | $7,000 | $7,000 | $1,000 |
| Common Stock | $7,000 | $7,000 | $7,000 | $1,000 |
| Long Term Capital Lease Obligation | $463,000 | $1,980,000 | $4,237,000 | $0 |
| Current Capital Lease Obligation | $1,518,000 | $2,257,000 | $2,040,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,992,000 | $16,790,000 | $15,231,000 | $4,280,000 |
| Current Accrued Expenses | $13,957,000 | $40,934,000 | $23,081,000 | $8,744,000 |
| Net PPE | $2,732,000 | $6,411,000 | $8,135,000 | $474,000 |
| Accumulated Depreciation | $-1,359,000 | $-1,628,000 | $-540,000 | $-53,000 |
| Gross PPE | $4,091,000 | $8,039,000 | $8,675,000 | $527,000 |
| Leases | $176,000 | $176,000 | $176,000 | $50,000 |
| Construction In Progress | $221,000 | $589,000 | $803,000 | $139,000 |
| Other Properties | $1,771,000 | $3,725,000 | $5,524,000 | - |
| Machinery Furniture Equipment | $1,923,000 | $3,549,000 | $2,172,000 | $338,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $0 | - | $937,000 | $0 |
| Work In Process | $0 | - | $1,681,000 | $0 |
| Raw Materials | $0 | - | $7,151,000 | $0 |
| Other Short Term Investments | $99,110,000 | $201,161,000 | $284,419,000 | $45,927,000 |
| Preferred Stock | - | $0 | $0 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-167,804,000 | $10,678,000 | $-182,397,000 | $-75,152,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-167,647,000 | $11,919,000 | $-179,871,000 | $-74,799,000 |
| Cash Flow From Continuing Operating Activities | $-167,647,000 | $11,919,000 | $-179,871,000 | $-74,799,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-157,000 | $-1,241,000 | $-2,526,000 | $-353,000 |
| Investing Cash Flow | $75,654,000 | $92,053,000 | $-238,988,000 | $-46,406,000 |
| Cash Flow From Continuing Investing Activities | $75,654,000 | $92,053,000 | $-238,988,000 | $-46,406,000 |
| Net Other Investing Changes | $-36,203,000 | - | - | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $348,000 | $3,543,000 | $431,789,000 | $158,506,000 |
| Cash Flow From Continuing Financing Activities | $348,000 | $3,543,000 | $431,789,000 | $158,506,000 |
| Net Other Financing Charges | $-1,784,000 | $-3,451,000 | $-2,847,000 | $-2,733,000 |
| Issuance Of Capital Stock | - | $0 | $432,447,000 | $135,000,000 |
| Net Preferred Stock Issuance | - | $0 | $0 | $135,000,000 |
| Preferred Stock Issuance | - | $0 | $0 | $135,000,000 |
| Net Common Stock Issuance | - | $0 | $432,447,000 | $0 |
| Common Stock Issuance | - | $0 | $432,447,000 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Income Tax Paid Supplemental Data | $708,000 | $6,389,000 | $27,000 | $0 |
| End Cash Position | $78,837,000 | $170,920,000 | $63,245,000 | $50,380,000 |
| Beginning Cash Position | $170,920,000 | $63,245,000 | $50,380,000 | $13,066,000 |
| Effect Of Exchange Rate Changes | $-438,000 | $160,000 | $-65,000 | $13,000 |
| Changes In Cash | $-91,645,000 | $107,515,000 | $12,930,000 | $37,301,000 |
| Proceeds From Stock Option Exercised | $2,132,000 | $6,994,000 | $2,189,000 | $343,000 |
| Net Investment Purchase And Sale | $112,014,000 | $93,294,000 | $-236,462,000 | $-46,053,000 |
| Sale Of Investment | $344,000,000 | $394,120,000 | $179,411,000 | $3,000,000 |
| Purchase Of Investment | $-231,986,000 | $-300,826,000 | $-415,873,000 | $-49,053,000 |
| Net PPE Purchase And Sale | $-157,000 | $-1,241,000 | $-2,526,000 | $-353,000 |
| Purchase Of PPE | $-157,000 | $-1,241,000 | $-2,526,000 | $-353,000 |
| Change In Working Capital | $-45,831,000 | $-65,661,000 | $-1,641,000 | $4,595,000 |
| Change In Other Current Liabilities | $-2,256,000 | $-2,041,000 | $-917,000 | $0 |
| Change In Payables And Accrued Expense | $-78,912,000 | $37,479,000 | $27,906,000 | $9,100,000 |
| Change In Accrued Expense | $-59,810,000 | $21,597,000 | $26,052,000 | $8,430,000 |
| Change In Payable | $-19,102,000 | $15,882,000 | $1,854,000 | $670,000 |
| Change In Account Payable | $-19,102,000 | $15,882,000 | $1,854,000 | $670,000 |
| Change In Prepaid Assets | $4,988,000 | $-3,226,000 | $-5,221,000 | $-4,486,000 |
| Change In Inventory | $-9,253,000 | $-73,129,000 | $-9,769,000 | $0 |
| Change In Receivables | $39,602,000 | $-24,744,000 | $-14,819,000 | $-144,000 |
| Changes In Account Receivables | $39,602,000 | $-24,744,000 | $-15,306,000 | $0 |
| Other Non Cash Items | $37,161,000 | - | - | $5,228,000 |
| Stock Based Compensation | $33,038,000 | $37,161,000 | $21,714,000 | $3,136,000 |
| Asset Impairment Charge | $118,680,000 | $0 | - | - |
| Amortization Of Securities | $-9,856,000 | $-9,940,000 | $-2,056,000 | $121,000 |
| Depreciation Amortization Depletion | $904,000 | $1,088,000 | $487,000 | $52,000 |
| Depreciation And Amortization | $904,000 | $1,088,000 | $487,000 | $52,000 |
| Depreciation | $904,000 | $1,088,000 | $487,000 | $52,000 |
| Net Income From Continuing Operations | $-301,743,000 | $49,271,000 | $-198,375,000 | $-87,931,000 |
| Repayment Of Debt | - | $0 | $0 | $-263,000 |
| Issuance Of Debt | - | $0 | $0 | $26,159,000 |
| Net Issuance Payments Of Debt | - | $0 | $0 | $25,896,000 |
| Net Long Term Debt Issuance | - | $0 | $0 | $25,896,000 |
| Long Term Debt Payments | - | $0 | $0 | $-263,000 |
| Long Term Debt Issuance | - | $0 | $0 | $26,159,000 |
| Change In Other Current Assets | - | $1,568,000 | $1,179,000 | $125,000 |
| Change In Interest Payable | - | $0 | $0 | $-2,000 |